Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

Historic Restructuring Costs for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $8.8 million.

  • BridgeBio Pharma's Restructuring Costs rose 9132.22% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 2779.87%. This contributed to the annual value of $15.6 million for FY2024, which is 9688.37% up from last year.
  • Per BridgeBio Pharma's latest filing, its Restructuring Costs stood at $8.8 million for Q3 2025, which was up 9132.22% from $805000.0 recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Restructuring Costs high stood at $22.7 million for Q1 2022, and its period low was $272000.0 during Q3 2023.
  • Its 4-year average for Restructuring Costs is $5.2 million, with a median of $3.5 million in 2023.
  • Its Restructuring Costs has fluctuated over the past 5 years, first plummeted by 9457.74% in 2023, then skyrocketed by 159889.71% in 2024.
  • BridgeBio Pharma's Restructuring Costs (Quarter) stood at $7.7 million in 2022, then crashed by 90.2% to $754000.0 in 2023, then surged by 522.41% to $4.7 million in 2024, then soared by 88.39% to $8.8 million in 2025.
  • Its Restructuring Costs was $8.8 million in Q3 2025, compared to $805000.0 in Q2 2025 and $570000.0 in Q1 2025.